Price T Rowe Associates Inc. MD Buys 54,900 Shares of AlloVir, Inc. (NASDAQ:ALVR)

Price T Rowe Associates Inc. MD boosted its stake in AlloVir, Inc. (NASDAQ:ALVR) by 127.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,986 shares of the company’s stock after purchasing an additional 54,900 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.09% of AlloVir worth $74,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ALVR. Twin Focus Capital Partners LLC bought a new stake in AlloVir in the 4th quarter worth approximately $40,000. Marquette Asset Management LLC bought a new stake in AlloVir in the 1st quarter worth approximately $135,000. Pennant Investors LP bought a new stake in AlloVir in the 4th quarter worth approximately $147,000. BML Capital Management LLC bought a new stake in AlloVir in the 1st quarter worth approximately $151,000. Finally, Acadian Asset Management LLC grew its position in AlloVir by 694.6% in the 1st quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock worth $1,197,000 after purchasing an additional 1,387,666 shares during the period. Institutional investors own 66.05% of the company’s stock.

AlloVir Price Performance

Shares of ALVR stock opened at $0.74 on Monday. AlloVir, Inc. has a 1 year low of $0.58 and a 1 year high of $3.75. The firm has a fifty day moving average price of $0.76 and a 200-day moving average price of $0.75. The company has a market cap of $85.44 million, a price-to-earnings ratio of -0.45 and a beta of 0.78.

AlloVir (NASDAQ:ALVR) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. Equities research analysts expect that AlloVir, Inc. will post -0.31 EPS for the current year.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.